RxDoctor Payments Data

Jessica Haugen

Family Medicine · Los Angeles, CANPI 1487215372

Payments from drug & device makers

$1,486in general payments, 2019–2025

Across 70 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$346
  • AbbVie$214
  • Pfizer$177
  • Novo Nordisk$148
  • Dexcom, Inc.$140
  • Amgen$90
  • plus $370 from 11 others

What the payments were for

  • Food & beverage$1,486100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,486 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$37,186
Medicare patients
105
Services billed
470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin93$64,515
OzempicSemaglutide55$50,623
TrulicityDulaglutide34$30,821
EliquisApixaban30$25,432
MounjaroTirzepatide25$24,761
XareltoRivaroxaban24$20,856
FarxigaDapagliflozin Propanediol32$20,505
Synjardy XrEmpagliflozin/Metformin Hcl22$13,034
RybelsusSemaglutide12$11,421
TradjentaLinagliptin12$11,319
Cinacalcet Hcl11$10,460
JanuviaSitagliptin Phosphate11$9,924
ShingrixVaricella-Zoster Ge/As01b/Pf18$3,582
Atorvastatin Calcium347$2,271
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$2,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$51$88,868127 claims
Novo NordiskOzempic, Rybelsus$148$62,04467 claims
Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30$346$56,93883 claims
PfizerEliquis$177$25,43230 claims
AstraZenecaFarxiga$35$20,50532 claims
MerckJanuvia$59$9,92411 claims
GSKShingrix$28$3,58218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →